skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Please update your opinion on CVLT including details on guidance and any contract wins. It came onto my radar after Ryan made an appearance touting it as one to watch. On Sept 4, you mentioned in a question that it was ok but expensive and preferred others. At $120-125 per share does it represent an opportunity or is it still expensive? Why or why not and if NO, at what price does it become a yes based on potential?
Read Answer Asked by Tim on December 05, 2025
Q: Can you please update your opinion of PSN based on the news from today and negative market reaction? What did the market not like with the new contract?
Would you recommend a new position if it can be bought below $73 or is there another level, time period or follow up news item that you would need to see before initiating a new position? Finally, would you rank it in your top group of favourite growth stocks after today's news and market reaction? If not, please state two that look better based on this weeks news and market activity
Read Answer Asked by Tim on December 05, 2025
Q: Do you have a preference between AEP and DUK? My objective is to add some stability and balance to an otherwise aggressive portfolio. I looked at FTS and EMA, but I have limited understanding of the Canadian market. If you believe a Canadian utility offers better growth potential, I would appreciate your insight and any suggestions you may have, given this objective. (Canadian taxpayer; this is for a tax-deferred acc).
Read Answer Asked by Adam on December 04, 2025
Q: I understand there has been some type of study which shows people who have taken the Shingles vaccine are less likely to develop Alzheimer’s like diseases. The scientific community seems not to know why this is so. There are a lot of unknowns on this study to say the least. Do you know any first rate Pharma companies that are leaders in the development and manufacturing the Shingles vaccines? I know there are a number of Shingles vaccines out in the marketplace, probably made by different companies. Does Bloomberg have anything to say on the subject? Any thoughts you have would be appreciated.
Jim
Read Answer Asked by James on December 04, 2025
Q: Hello 5i,

We have listed a few Ugly Ducklings of the year below. Please rank the following stocks for purchase today with a longer-term view on growth.

CRM, MRVL, TRI, CSU, LMN, CROX, UNH, HD, GSY, FOUR, AVAV

Thank you for your sage advice.

D&J
Read Answer Asked by Jerry on December 04, 2025
Q: Trex has declined significantly since March of 2024. I had purchased some stock just before the precipitous decline at the beginning of November this year and am now down about 50% on 1/2 a position.

This creates a question; is the stock now dead money until the US consumer economy sorts itself out (which I think is a few years away at least), or is this a buying opportunity today to fill the remainder of a position and wait it out?

Trex is a leader in its' market, yet requires new home and renovation build out to successful. The precipitous drop has now brought it to analysts attention as they try to resolve questions similar to my own.

Would you be a buyer, and if so with what time frame in mind, or would you sell and come back to it in a few years?

Thanks as always, and best of the season to you all!

Dave
Read Answer Asked by Dave on December 04, 2025
Q: NDVA's price as of today $181.46
NCDA's fair value given by Morningstar $191.38
Given NVDA's incredible run in the past few years, I have a hard time wrapping my brain about the idea that NVDA is actually "cheaper" than its fair value.
Would you add to NVDA at this point?
I have a significant position in NVDA already so I am very invested.
Read Answer Asked by Anh on December 04, 2025